Alnylam Pharmaceuticals, Inc. (ALNY) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2026
Loading P/E history...
ALNY Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a price-to-earnings ratio of 127.0x, with a stock price of $295.91 and trailing twelve-month earnings per share of $4.18.
The current P/E is 82% below its 5-year average of 718.2x. Over the past five years, ALNY's P/E has ranged from a low of 78.6x to a high of 1900.0x, placing the current valuation at the 33th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ALNY trades at a 469% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ALNY commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALNY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ALNY P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74B | 17.1Lowest | 2.70Best | +8%Best | |
| $28B | 21.7 | - | -21% | |
| $10B | 30.1 | - | -19% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ALNY Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $330.89 | $4.21 | 78.6x | -89% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $397.65 | $2.26 | 176.0x | -76% |
| FY2025 Q3 | $456.00 | $0.24 | 1900.0x | +165% |
Average P/E for displayed period: 718.2x
Full ALNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ALNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALNY — Frequently Asked Questions
Quick answers to the most common questions about buying ALNY stock.
Is ALNY stock overvalued or undervalued?
ALNY trades at 127.0x P/E, below its 5-year average of 718.2x. At the 33th percentile of historical range, the stock is priced at a discount to its own history.
How does ALNY's valuation compare to peers?
Alnylam Pharmaceuticals, Inc. P/E of 127.0x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is ALNY's PEG ratio?
ALNY PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2026.